• Home
  • Clearstate Insights

Latest Clearstate Insights posts

Clearstate provides up-to-date healthcare intelligence  - trends and insights - for the surgical and diagnostics sectors.

Filters

How Indonesia’s healthcare transformation will impact its IVD market

Indonesia’s in-vitro diagnostics (IVD) market will recover…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)

How inflation will impact Brazil’s IVD market

Brazil’s in-vitro diagnostics (IVD) market will recover in…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Uncategorised | Americas
How Vision 2030 is driving growth in the Saudi Arabia IVD market

How Vision 2030 is driving growth in Saudi Arabia’s IVD market

The incidence of cardiovascular diseases (CVD) in…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx)
Middle East IVD market to recover to pre-pandemic growth rates from 2024

Middle East IVD market to recover to pre-pandemic growth rates from 2024

The Middle East IVD market has mostly recovered to…

Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

The impact of China’s latest covid-19 surge heads the…

Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels

Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels

Asia-Pacific (APAC) IVD markets have grown and exceeded…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most-commonly tested cancer biomarkers using NGS in Europe: RAS, BRAF, EGFR

Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR

Most-commonly tested cancer biomarkers using NGS in Europe…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5

Larger gene panels are the predominant NGS testing strategy in EU5

Larger gene panels are the predominant NGS testing strategy…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Precision medicine and access to NGS cancer biomarker testing in Europe

Europe: precision medicine and access to NGS cancer biomarker testing

Precision medicine and access to NGS cancer biomarker…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Proportion of cancer biomarker testing done with NGS…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
covid-19 diagnostics in Europe

Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen

Europe is shifting its covid-19-approach from pandemic to…

Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Molecular Diagnostics (MDx) | Europe | IVD Gateway | Molecular Diagnostics (MDx)
Osaka skyline

Ageing and the Impact on Japan’s IVD Market

In this report “Ageing and the Impact on Japan’s IVD…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Asia | IVD Gateway